Ventas Reports 2022 Fourth Quarter and Full Year Results and Provides 2023 Outlook
Retrieved on:
Giovedì, Febbraio 9, 2023
Commercial Building & Real Estate, Seniors, Construction & Property, Finance, Professional Services, REIT, Consumer, Other Construction & Property, Science Based Targets initiative, Assembly, Health care, Investment, Office, Medicine, R&I, EVP, Target, Acquisition, Carbon, GAAP, Research, ESG, The Assembly, Melody Barnes, Normalization, Education, CIO, SHOP, MOB, Ardent Health Services, Retirement, University School, Certification, R, LEED, Renewable energy, Pharmaceutical industry, Management, Ventas
Consistent with its strategic capital allocation priorities, Ventas closed or committed $1.2 billion in total investments in 2022:
Key Points:
- Consistent with its strategic capital allocation priorities, Ventas closed or committed $1.2 billion in total investments in 2022:
Notably, Ventas continued expanding its life science, R&I footprint, as evidenced by $0.7 billion in closed or committed projects in 2022. - Consistent with the Company’s pre-pandemic practice, the Company is reintroducing full year guidance for 2023.
- The Company’s 2023 guidance contains forward-looking statements and is based on a number of assumptions; actual results may differ materially.
- Ventas expects to report 2023 per share attributable net income to common stockholders, Nareit FFO and Normalized FFO within the following ranges: